-+ 0.00%
-+ 0.00%
-+ 0.00%

AbCellera Q3 2026 loss per share narrows 32% to USD 0.13

PUBT·11/09/2026 21:13:32
Listen to the news
AbCellera Q3 2026 loss per share narrows 32% to USD 0.13
  • AbCellera’s Q3 2026 net loss narrowed 29% year over year to USD 40.8 million.
  • Revenue rose 18% year over year to USD 10.6 million, while research and development expenses fell 21% to USD 43.5 million.
  • Available liquidity exceeded USD 890 million at September 30, 2026, including over USD 790 million in cash balances and marketable securities.
  • ABCL635 is expected to enter late-stage development in 2027; development of ABCL575 will not proceed beyond Phase 1 under current plans.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abcellera Biologics Inc. published the original content used to generate this news brief on November 09, 2026, and is solely responsible for the information contained therein.